dr. (Pieter) PHM van Baal

Associate Professor Erasmus School of Health Policy & Management Health Economics (HE)

Location: Burg. Oudlaan 50, Rotterdam
Room: J8-43
Telephone: 0104089118
Email: vanbaal@eshpm.eur.nl

Profile

Pieter van Baal is an associate professor of Health Economics. His research focuses on the methodology of cost effectiveness analayses, modeling of diseases/population health and the relation thereof with (non)medical consumption. He has extensive experience in economic evaluations of public health interventions, Markov modeling, uncertainty analyses and is the main developer of PAID (Practical Application to Include future Disease costs). Before working at iBMG/iMTA he was employed by the National Institute for Public Health and the Environment (RIVM) where he was project leader of the RIVM Chronic Disease Model.

- - - T. Blakely, C. Cleghorn, F. Petrović-van der Deen, L.J. Cobiac, A. Mizdrak, J. Mackenbach, A. Woodward, P.H.M. van Baal & N. Wilson (2020). Prospective impact of tobacco eradication and overweight and obesity eradication on future morbidity and health-adjusted life expectancy: simulation study. Journal of Epidemiology and Community Health. doi: 10.1136/jech-2019-213091
    - J.J. Brugts, J.F. Veenis, S.P. Radhoe, G. LInsssen, M. Van Gent, C.J.W. Borleffs, J. van Ramhorst, P. van Pol, R. Tukkie, R. Spee, M. Emans, W. Kok, V. van Halm, L. Handoko, S. Beeres, M. Post, E. Boersma, M.J. Lenzen, O.C. Manintveld, H. Koffijberg, P.H.M. van Baal, M.M. Versteegh, T. Smilde, L. van Heerebeek, M. Rienstra, A. Mosterd, P. Delnoy, F.W. Asselbergs, H. Brunner-La Rocca & R. de Boer (2020). A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure : Design and rationale of the MONITOR HF multicentre randomised clinical trial. Netherlands Heart Journal, 28 (1), 16-26. doi: 10.1007/s12471-019-01341-9
    - P.H.M. van Baal, A. Morton, D. Meltzer & W.B.F. Brouwer (2019). Future unrelated medical costs need to be considered in cost effectiveness analysis. The European Journal Of Health Economics, 20, 1-5. doi: 10.1007/s10198-018-0976-0
    - W.B.F. Brouwer, P.H.M. van Baal, N.J.A. van Exel & M.M. Versteegh (2019). When is it too expensive? Cost-effectiveness thresholds and health care decision making. The European Journal Of Health Economics, 20 (2), 175-180. doi: 10.1007/s10198-018-1000-4
    - M.G. Franken, B. Leeneman, M. Gheorghe, C.A. Uyl - de Groot, J. Haanen & P.H.M. van Baal (2019). A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European Journal of Cancer, 123, 58-71. doi: 10.1016/j.ejca.2019.08.032 [go to publisher's site]
    - L. De Vries, P.H.M. van Baal & W.B.F. Brouwer (2019). Future costs in economic evaluations: past, present, future. Pharmacoeconomics (Print), 37 (2), 119-130. doi: 10.1007/s40273-018-0749-8
    - P.H.M. van Baal, M. Perry-Duxbury, P.L.H. Bakx, M.M. Versteegh, E.K.A. van Doorslaer & W.B.F. Brouwer (2019). A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Economics, 28 (1), 87-100. doi: 10.1002/hec.3831
    - S. Ratushnyak, M. Hoogendoorn & P.H.M. van Baal (2019). Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained. American Journal of Preventive Medicine, 57 (6), 792-799. doi: 10.1016/j.amepre.2019.07.027
    - L.M. de Vries, P.H.M. van Baal & W.B.F. Brouwer (2018). Future Costs in Cost-Effectiveness Analyses: Past. Present, Future. Pharmacoeconomics (Online). doi: 10.1007/s40273-018-0749-8
    - W.B.F. Brouwer, P.H.M. van Baal, N.J.A. van Exel & M.M. Versteegh (2018). When is it too expensive? Cost-effectiveness thresholds and health care decision-making. European Journal of Health Economics (HEPAC). doi: 10.1007/s10198-018-1000-4
    - P.H.M. van Baal, A. Morton, D. Meltzer & W.B.F. Brouwer (2018). Future unrelated medical costs need to be considered in cost effectiveness analysis. European Journal of Health Economics (HEPAC). doi: 10.1007/s10198-018-0976-0
    - P.H.M. van Baal, M.S. Perry-Duxbury, P.L.H. Bakx, M.M. Versteegh, E.K.A. van Doorslaer & W.B.F. Brouwer (2018). A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Economics, 28 (1), 87-100. doi: 10.1002/hec.3831
    - P.H.M. van Baal, A. Morton & J.L. Severens (2018). Health care input constraints and cost effectiveness analysis decision rules. Social Science & Medicine, 200 (March), 59-64. doi: 10.1016/j.socscimed.2018.01.026.
    - P.H.M. van Baal & M. Gheorghe (2017). We leven langer, maar ook in goede gezondheid? Ongelijkheid in voor kwaliteit van leven gecorrigeerde levensverwachting. Nederlands Tijdschrift voor Geneeskunde, 161 (8):D806.
    - M. Gheorghe, S. Picavet, M. Verschuren, W.B.F. Brouwer & P.H.M. van Baal (2017). Health losses at the end of life: a Bayesian mixed beta regression approach. Journal of the Royal Statistical Society. Series A. Statistics in Society, 180 (3), 723-749. doi: 10.1111/rssa.12230
    - F. Alleweldt, S. Kara, A. Osinski, P.H.M. van Baal, K.M. Kellerborg, F.M. Aarestrup & M.P.G. Koopmans (2017). Developing a framework to assess the costeffectiveness of COMPARE - a global platform for the exchange of sequence-based pathogen data. Revue Scientifique et Technique de l'Office International des Epizooties, 36 (1), 311-322. doi: 10.20506/rst.36.1.2631.
    - P.H.M. van Baal, A. Morton, D.O. Meltzer & W.B.F. Brouwer (2017). Should cost effectiveness analyses for NICE always consider future unrelated medical costs? BMJ-British medical journal, Nov 10, 359-359. doi: 10.1136/bmj.j5096 [go to publisher's site]
    - R.T. Hoogenveen, H.C. Boshuizen, P. Engelfriet & P.H.M. van Baal (2017). You Only Die Once: Accounting for Multi-Attributable Mortality Risks in Multi-Disease Models for Health-Economic Analyses. Medical Decision Making, 37 (4), 403-414. doi: 10.1177/0272989X16658661
    - M. Gheorghe, P. Wubulihasimu, F. Peters, W.J. Nusselder & P.H.M. van Baal (2016). Health inequalities in the Netherlands: trends in quality-adjusted life expectancy (QALE) by educational level. European Journal of Public Health, 26 (5), 794-799. doi: 10.1093/eurpub/ckw043
    - A. Morton, A.L. Adler, D. Bell, A. Briggs, W.B.F. Brouwer, K. Claxton, N. Craig, A. Fischer, P. McGregor & P.H.M. van Baal (2016). Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. Health Economics, 25 (8), 933-938. doi: 10.1002/hec.3366
    - P. Wubulihasimu, W.B.F. Brouwer & P.H.M. van Baal (2016). The Impact of Hospital Payment Schemes on Healthcare and Mortality: Evidence from Hospital Payment Reforms in OECD Countries. Health Economics, 25 (8), 1005-1019. doi: 10.1002/hec.3205
    - P.H.M. van Baal, F. Peters, J.P. Mackenbach & W.J. Nusselder (2016). Forecasting differences in life expectancy by education. Population Studies. A Journal of Demography, 70 (2), 201-216. doi: 10.1080/00324728.2016.1159718
    - P.H.M. van Baal, M. Hoogendoorn & A. Fischer (2016). Preventing dementia by promoting physical activity and the long-term impact on health and social care expenditures. Preventive Medicine, 85 (4), 78-83. doi: 10.1016/j.ypmed.2016.01.013
    - P.H.M. van Baal, D. Meltzer & W.B.F. Brouwer (2016). Future costs, fixed healthcare budgets and the decision rules of cost-effectiveness analysis. Health Economics, 25 (2), 237-248. doi: 10.1002/hec.3138
    - P.H.M. van Baal (2015). Preventie minder noodzakelijk dankzij betere zorg? Naar een doelmatige inzet van preventie en curatie. Nederlands Tijdschrift voor Geneeskunde, 159 (19). [go to publisher's site]
    - M. Gheorghe, W.B.F. Brouwer & P.H.M. van Baal (2015). Quality of life and time to death: have the health gains of preventive interventions been underestimated? Medical Decision Making, 35 (3), 316-327. doi: 10.1177/0272989X14555771
    - M. Gheorghe, W.B.F. Brouwer & P.H.M. van Baal (2015). Did the health of the Dutch population improve between 2001 and 2008? Investigating age- and gender-specific trends in quality of life. European Journal of Health Economics (HEPAC), 16 (8), 801-811. doi: 10.1007/s10198-014-0630-4
    - P. Wubulihasimu, W.B.F. Brouwer & P.H.M. van Baal (2015). Does living longer in good health facilitate longer working lives? The relationship between disability and working lives. European Journal of Public Health, 25 (5), 791-795. doi: 10.1093/eurpub/ckv062.
    - I. Grootjans-van Kampen, P. Engelfriet & P.H.M. van Baal (2014). Disease Prevention: Saving Lives or Reducing Health Care Costs? PLoS One (print), 9 (8):e104469. doi: 10.1371/journal.pone.0104469
    - P. Wubulihasimu, M. Gheorghe, L. Slobbe, J. Polder & P.H.M. van Baal (2014). Trends in Dutch hospital spending by age and disease1994–2010. Health Policy. doi: 10.1016/j.healthpol.2014.11.009
    - I.M. Majer, J.P. Mackenbach & P.H.M. van Baal (2013). Time trends and forecasts of body mass index from repeated cross-sectional data: a different approach. Statistics in Medicine, 32, 1561-1571. doi: 10.1002/sim.5558
    - P.H.M. van Baal, D. Meltzer & W.B.F. Brouwer (2013). Pharmacoeconomics Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al. Pharmacoeconomics (Print), 31, 369-373. doi: 10.1007/s40273-013-0042-9
    - T.A. Kanters, W.B.F. Brouwer, R.C.J.A. van Vliet, P.H.M. van Baal & J. Polder (2013). A new prevention paradox: The trade-off between reducing incentives for risk selection and increasing the incentives for prevention for health insurers. Social Science & Medicine, 76, 150-158. doi: 10.1016/j.socscimed.2012.10.019
    - I.M. Majer, R. stevens, W.J. Nusselder, J.P. Mackenbach & P.H.M. van Baal (2013). Modeling and Forecasting Health Expectancy: Theoretical Framework and Application. Demography, 50, 673-697. doi: 10.1007/s13524-012-0156-2
    - L. Mohseninejad, P.H.M. van Baal, M. van den Berg, E. Buskens & T.L. Feenstra (2013). Value of information analysis from a societal perspective: a case study in prevention of major depression. Value in Health, 16 (4), 490-497. doi: 10.1016/j.jval.2012.12.007
    - E. Over, W. Wendel-Vos, M. Berg, H. Hamberg-van Reenen, L. Tariq, R.T. Hoogenveen & P.H.M. van Baal (2012). Cost-effectiveness of counseling and pedometer use to increase physical activity in the Netherlands: a modeling study. Cost Effectiveness and Resource Allocation, 10 (1), 1-7. doi: 10.1186/1478-7547-10-13
    - H.C. Boshuizen, S.K. Lhachimi, P.H.M. van Baal, R.T. Hoogenveen, H.A. Smit, J.P. Mackenbach & W.J. Nusselder (2012). The DYNAMO-HIA Model: An Efficient Implementation of a Risk Factor/Chronic Disease Markov Model for Use in Health Impact Assessment (HIA). Demography, 49 (4), 1259-1283. doi: 10.1007/s13524-012-0122-z
    - I.M. Majer, J.P. Mackenbach & P.H.M. van Baal (2012). Time trends and forecasts of body mass index from repeated cross-sectional data: a different approach. Statistics in Medicine. doi: 10.1002/sim.5558 [go to publisher's site]
    - P.H.M. van Baal (2012). Important cost categories not included: transcatheter aortic valve implantation probably less cost-effective. Heart, 98, 1182-1182. doi: 10.1136/heartjnl-2012-302272
    - C.A.M. De Meijer, M. Majer, M.A. Koopmanschap & P.H.M. van Baal (2012). Forecasting Lifetime and Aggregate Long-term Care Spending - Accounting for Changing Disability Patterns. Medical Care, 50 (8), 722-729. doi: 10.1097/MLR.0b013e31824ebddc
    - P.H.M. van Baal & A. Wong (2012). Time to death and the forecasting of macro-level health care expenditures: Some further considerations. Journal of Health Economics, 31 (2012), 876-887. doi: 10.1016/j.jhealeco.2012.08.003
    - J. van de Kassteele, R.T. Hoogenveen, P.M. Engelfriet, P.H.M. van Baal & H.C. Boshuizen (2012). Estimating net transition probabilities from cross-sectional data with application to risk factors in chronic disease modeling. Statistics in Medicine, 31, 533-543. doi: 10.1002/sim.4423
    - C.A.M. de Meijer, I.M. Majer, M.A. Koopmanschap & P.H.M. van Baal (2012). Forecasting Lifetime and Aggregate Long-term Care Spending Accounting for Changing Disability Patterns. Medical Care, 50 (8), 722-729. doi: 10.1097/MLR.0b013e31824ebddc
    - S.K. Lhachimi, W.J. Nusselder, H.A. Smit, P.H.M. van Baal, P. Baili, K. Bennett, E. Fernandez, M.C. Kulik, T. Lobstein, J. Pomerleau, J.P. Mackenbach & H.C. Boshuizen (2012). DYNAMO-HIA-A Dynamic Modeling Tool for Generic Health Impact Assessments. PLoS One (print), 7 (5), 1-11. doi: 10.1371/journal.pone.0033317
    - P.H.M. van Baal, A. Wong, L.C.J. Slobbe, J.J. Polder, W.B.F. Brouwer & G.A. de Wit (2011). Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations. Pharmacoeconomics (Print), 29 (3), 175-187. doi: 10.2165/11586130-000000000-00000
    - R. Heijink, P.H.M. van Baal, M. Oppe, X.H.E. Koolman & G.P. Westert (2011). Decomposing cross-country differences in quality adjusted life expectancy: the impact of value sets. Population Health Metrics, 9 (17), 1-11. doi: 10.1186/1478-7954-9-17
    - P.H.M. van Baal & W.B.F. Brouwer (2011). PAID 1.0 in Practice A Brief Clarification Regarding its Possibilities and Limitations. Pharmacoeconomics (Print), 29 (6), 545-547. doi: 10.2165/11585600-000000000-00000
    - P.H.M. van Baal, P. Engelfriet, R.T. Hoogenveen, M.J.J.C. Poos, C. van den Dungen & H.C. Boshuizen (2011). Estimating and comparing incidence and prevalence of chronic diseases by combining GP registry data: the role of uncertainty. BMC Public Health, 11 (163), 1-11. doi: 10.1186/1471-2458-11-163
    - P. Engelfriet, R.T. Hoogenveen, H.C. Boshuizen & P.H.M. van Baal (2011). To die with or from heart failure: a difference that counts. Is heart failure underrepresented in national mortality statistics. European Journal of Heart Failure, 13, 377-383.
    - P.H.M. van Baal, T.L. Feenstra, J.J. Polder, R.T. Hoogenveen & W.B.F. Brouwer (2011). Economic Evaluation and the postponement of health care costs. Health Economics, 20, 432-445. doi: 10.1002/hec.1599
    - T.L. Feenstra, P.H.M. van Baal, M.O. Jacobs-van der Bruggen, R.T. Hoogenveen, G.J. Kommer & C.A. Baan (2011). Targeted versus universal prevention. a resource allocation model to prioritize cardiovascular prevention. Cost Effectiveness and Resource Allocation, 9 (14), 1-11. doi: 10.1186/1478-7547-9-14
    - A. Wong, P.H.M. van Baal, H.C. Boshuizen & J.J. Polder (2011). Exploring the influence of proximity to death on disease-specific hospital expenditures: a carpaccio of red herrings. Health Economics, 20 (4), 379-400. doi: 10.1002/hec.1597
    - P.H.M. van Baal, P.M. Engelfriet, H.C. Boshuizen, J. van de Kassteele, F.G. Schellevis & R.T. Hoogenveen (2011). Co-occurrence of diabetes, myocardial infarction, stroke, and cancer: quantigying age patterns in the Dutch population using health survey data. Population Health Metrics, 9 (51), 1-9. doi: 10.1186/1478-7954-9-51
    - I.M. Majer, W.J. Nusselder, J.P. Mackenbach, B. Klijs & P.H.M. van Baal (2011). Mortality Risk Associated With Disability: A Population-Based Record Linkage Study. American Journal of Public Health, 101 (12), 9-15. doi: 10.2105/AJPH.2011.300361
    - M. van den Berg, F. Smit, T. Vos & P.H.M. van Baal (2011). Cost-Effectiveness of Opportunistic Screening and Minimal Contact Psycotherapy to Prevent Depression in Primary Care Patients. PLoS One (print), 6 (87), 1-7. doi: 10.1371/journal.pone.0022884
    - M.A.M. Jacobs-van der Bruggen, A. Spijkerman, P.H.M. van Baal, C.A. Baan, E.J.M. Feskens, H.S. Picavet, D.L. van der A & W.M. Verschuren (2010). Weight Change and Incident Diabetes: Addressing an Unresolved Issue. American Journal of Epidemiology, 172 (3), 263-270. doi: 10.1093/aje/kwq134
    - P.H.M. van Baal & T.L. Feenstra (2010). Long-term effects of alcohol policies: an economic perspective. Addiction, 105, 395-396. doi: 10.1111/j.1360-0443.2009.02847.x
    - D.R. Rappange, W.B.F. Brouwer, F.F.H. Rutten & P.H.M. van Baal (2010). Lifestyle intervention: from cost savings to value for money. Journal of Public Health, 32 (3), 440-447. doi: 10.1093/pubmed/fdp079
    - P.H.M. van Baal, R.T. Hoogenveen, H.C. Boshuizen & P. Engelfriet (2010). Indirect Estimation of Chronic Disease Excess Mortality. Epidemiology, 21 (3), 1-2. doi: 10.1097/EDE.0b013e3181d7773f
    - D.R. Rappange, W.B.F. Brouwer, R.T. Hoogenveen & P.H.M. van Baal (2009). Healthcare Costs and Obesity Prevention Drug Costs and Other Sector-Specific Consequences. Pharmacoeconomics (Print), 27 (12), 1031-1044. doi: 10.2165/11319900-000000000-00000
    - D.R. Rappange, P.H.M. van Baal, N.J.A. van Exel, T.L. Feenstra, F.F.H. Rutten & W.B.F. Brouwer (2009). I costi sanitari indiretti (non correlati) durante gli anni di vita guadagnati: : Devono essere inclusi nelle valutazioni economiche degli interventi sanitari? Pharmacoeconomics Italian Research Articles, 11 (1), 55-70.
    - T.L. Feenstra, P.H.M. van Baal, A. Gandjour & W.B.F. Brouwer (2008). Future medical costs in economic evaluations. A comment on Lee. Journal of Health Economics, 27 (6), 1645-1649. doi: 10.1016/j.jhealeco.2008.07.007
    - P.H.M. van Baal, J.J. Polder, G.A. de Wit, R.T. Hoogeveen, T.L. Feenstra, H.C. Boshuizen, P. Engelfriet & W.B.F. Brouwer (2008). Lifetime medical costs of obesity: pevention no cure for increasing health expenditure. PLoS Medicine (print), 5 (2), 242-249. doi: 10.1371/journal.pmed.0050029
    - D.R. Rappange, P.H.M. van Baal, F.F.H. Rutten, N.J.A. van Exel, T.L. Feenstra & W.B.F. Brouwer (2008). Unrelated medical costs in life-years gained should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics (Print), 26 (10), 815-860. doi: 10.2165/00019053-200826100-00003
    - P.H.M. van Baal, T.L. Feenstra, R.T. Hoogenveen, G.A. de Wit & W.B.F. Brouwer (2007). Unrealated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio. Health Economics, 16, 421-433. doi: 10.1002/hec.1181
    - P.H.M. van Baal, W.B.F. Brouwer, R.T. Hoogeveen & T.L. Feenstra (2007). Increasing tobacco taxes: A cheap tool to increase public health. Health Policy, 82, 142-152. doi: 10.1016/j.healthpol.2006.09.004
    - W.B.F. Brouwer, N.J.A. van Exel, P.H.M. van Baal & J. Polder (2007). Economics and public health: Engaged to be happily married! European Journal of Public Health, 17 (2), 122-123. doi: 10.1093/eurpub/ckl074
  - - P.H.M. van Baal (2010). Economische evaluaties en de zorgkosten van levensverlenging. VGE Bulletin, 3, 26-28.
    - W.B.F. Brouwer, N.J.A. van Exel & P.H.M. van Baal (2008). Kosten in de gewonnen levensjaren niet langer negeren! TSG, 86 (1), 1-1.
    - P.H.M. van Baal, W.B.F. Brouwer, G.A. de Wit, R.T. Hoogeveen & J.J. Polder (2008). De invloed van roken en overgewicht op zorguitgaven. TSG, 86 (3), 150-155.
    - W.B.F. Brouwer, N.J.A. van Exel & P.H.M. van Baal (2007). De kosten in gewonnen levensjaren - tijd voor een nieuwe richtlijn! VGE Bulletin, 24 (1), 11-14.
    - W.B.F. Brouwer, N.J.A. van Exel, J. Polder & P.H.M. van Baal (2006). Gezond leven niet per se goedkoper. Medisch Contact, 61 (21), 878-881.
    - W.B.F. Brouwer, P.H.M. van Baal & N.J.A. van Exel (2006). De dubbele prijs van succes: The pain is in the gain. TSG, 84, 7-10.
- - - P.H.M. van Baal, H. Elffers & D.J. Hessing (2000). These: A System for Simulations of Rule-Breaking Behavior. In E. Hoelz (Ed.), Conference Proceedings Fairness and Cooperation (pp. 467-470). Vienna: IAREP/SABE
  - - N.J.A. van Exel, P.H.M. van Baal & W.B.F. Brouwer (2011). Prikkels voor gezond gedrag: een gezonde zaak? In HW van Lienden & JMD Boot (Eds.), Economie van de volksgezondheid: zorg voor gezondheid=zorg voor welvaart. Assen: van Gorcum
    - J. Polder, P.H.M. van Baal, N.J.A. van Exel & W.B.F. Brouwer (2007). Preventie: niet altijd goedkoop, wel vaak een goede koop. Een economisch verhaal over preventie en de waarde van gezondheid. In Jaarboek Publieke Gezondheid (pp. 128-3). Abcoude: Stichting Public Health Forum
    - J.J. Polder, P.H.M. van Baal, N.J.A. van Exel & W.B.F. Brouwer (2007). Een economisch verhaal over preventie en de waarde van gezondheid. In Jaarboek Publieke Gezondheid 2007 (pp. 128-3). Abcoude: Stichting Public Health Forum
- - - P.H.M. van Baal, N.J.A. van Exel & W.B.F. Brouwer (2015). Kosten van langer leven en de evaluatie van medische technologie. (Extern rapport, Opinion Paper 64). Tilburg: Netspar
    - P.H.M. van Baal, P. Obulqasim, W.B.F. Brouwer, W. Nusselder & J. Mackenbach (2013). The influence of health care spending on life expectancy. (Extern rapport). Tilburg: Netspar Panel Papers
    - H. Elffers, F.H. Barwegen, D.J. Hessing & P.H.M. van Baal (2000). Naleving van belastingregels, een literatuurinventarisatie 1992-1998. (Intern rapport, no 1). :
  - - H. Elffers, F.H. Barwegen, D.J. Hessing & P.H.M. van Baal (1999). Naleving van Belastingregels. (Extern rapport, no 2). Rotterdam: Erasmus Centre for Sociolegal Tax Research
    - P.H.M. van Baal, P.J. de Koning & D.J. Hessing (1999). Naar een model van kosten-effectiviteit van Justitiële Inrichtingen. (Extern rapport, no 1). Rotterdam: Onderzoekschool Maatschappelijke Veiligheid
- - P.H.M. van Baal & H.C. BoshuizenModeling Chronic Diseases in Relation to Risk Factors. . Retrieved Dec 14, 2019, from https://oxfordre.com/economics/view/10.1093/acrefore/9780190625979.001.0001/acrefore-9780190625979-e-275?print=pdf
- - W.B.F. Brouwer, F.F.H. Rutten, J.L. Severens, P.H.M. van Baal, T.E.D. van der Grinten, A.H.E. Koolman & N.J.A. van Exel (2011). Economie van de volksgezondheid. Assen: Koninklijke van Gorcum BV
- - P.H.M. van Baal (2004, april 1). Computer Simulations of Criminal Deterrence. Erasmus Universiteit Rotterdam (171 pag.) (Den Haag: Boom Juridische Uitgevers) Prom./coprom.: prof.mr. R.V. De Mulder.
- - M. Gheorghe (2016, september 15). Quantitative Approaches in Monitoring Population Quality Of Life. EUR Prom./coprom.: prof.dr. W.B.F. Brouwer & dr. P.H.M. van Baal.
  - I.M. Majer (2012, juni 22). Modelling and forecasting health expectancy. EUR (210 pag.) Prom./coprom.: Prof. Dr. J.P. Mackenbach & dr. P.H.M. van Baal.
Kwaliteit van Zorg
Title
Kwaliteit van Zorg
Year
2019
Year level
(bachelor 1)
Kwaliteit van Zorg
Title
Kwaliteit van Zorg
Year
2019
Year level
(bachelor 1)
Ziekte en Gezondheid
Title
Ziekte en Gezondheid
Year
2019
Year level
(bachelor 1)
Ziekte en Gezondheid
Title
Ziekte en Gezondheid
Year
2019
Year level
(bachelor 1)
Ziekte en Gezondheid
Title
Ziekte en Gezondheid
Year
2019
Year level
(bachelor 1)
Master Thesis HEPL
Title
Master Thesis HEPL
Year
2019
Year level
(master)
Public Health Economics
Title
Public Health Economics
Year
2019
Year level
(master) (master)
Global Health Economics
Title
Global Health Economics
Year
2019
Year level
(master) (master) (master) (master)
Master Thesis HE
Title
Master Thesis HE
Year
2019
Year level
(master) (master)
Sociaal Medische wetenschappen
Title
Sociaal Medische wetenschappen
Year
2019
Year level
(pre-master)
Understanding health behaviour
Title
Understanding health behaviour
Year
2019
Year level
(Bachelor 3)
PLoS One (online)
Role
Member Editorial Board
Associate Professor
University
Erasmus University Rotterdam
School
Erasmus School of Health Policy & Management
Department
Health Economics (HE)
Country
The Netherlands
Telephone
0104089118
institute of Health Policy & Management
Role
Chairman of the examination board
Obtained Wage
yes

Address

Visiting address

Burg. Oudlaan 50 3062 PA Rotterdam

Postal address

Postbus 1738 3000 DR Rotterdam

dr. (Pieter) PHM van Baal

More information

Profile

All publications (87)

Article (73)

Scholarly Publication (67)

Professional Publication (6)

Part of book - Chapter (4)

Scholarly Publication (1)

Professional Publication (3)

Report (5)

Scholarly Publication (3)

Professional Publication (2)

Website / portal (1)

Book / Monograph / Book editorial (1)

Doctoral thesis (1)

Supervised Theses (2)

Teaching (11)

Editorial positions (1)

PLoS One (online)

Present position

Associate Professor

Other positions (1)

institute of Health Policy & Management

Address

Visiting address

Postal address